Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction-Reference-Cited by-同舟云学术

Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction

Published:2021-08-03 Issue:15 Volume:64 Page:11148-11168
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

McKinney David C.¹^ORCID,McMillan Brian J.¹,Ranaghan Matthew J.¹^ORCID,Moroco Jamie A.¹^ORCID,Brousseau Merissa¹,Mullin-Bernstein Zachary²,O’Keefe Meghan¹,McCarren Patrick¹,Mesleh Michael F.¹,Mulvaney Kathleen M.²,Robinson Foxy²,Singh Ritu¹,Bajrami Besnik¹,Wagner Florence F.¹,Hilgraf Robert¹,Drysdale Martin J.¹,Campbell Arthur J.¹,Skepner Adam¹,Timm David E.³,Porter Dale²,Kaushik Virendar K.¹,Sellers William R.²⁴,Ianari Alessandra²^ORCID

Affiliation:

1. Center for the Development of Therapeutics, The Broad Institute of MIT and Harvard, 415 Main Street, Cambridge, Massachusetts 02142, United States

2. Cancer Program, The Broad Institute of MIT and Harvard, 415 Main Street, Cambridge, Massachusetts 02142, United States

3. Department of Biochemistry, University of Utah, 1390 Presidents Circle, Salt Lake City, Utah 84112, United States

4. Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02215, United States

Funder

National Institutes of Health

Broad Institute

Deerfield management

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00507

Reference24 articles.

1. Proteomics profiling of arginine methylation defines PRMT5 substrate specificity